Anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells

Journal Article · Thu May 15 00:00:00 EDT 1986 · J. Immunol.; (United States)

OSTI ID:5650996

Mule, J J; Yang, J; Shu, S; Rosenberg, S A

Our previous studies demonstrated that the incubation of human peripheral blood lymphocytes or murine splenocytes in recombinant interleukin 2 (RIL 2) resulted in the generation of lymphokine-activated killer (LAK) cells capable of lysing a broad spectrum of fresh tumors in short-term chromium-release assays. Moreover, injections of LAK cells plus RIL 2 were highly effective in eliminating established 3 day metastases in the lung and liver. We have examined several parameters to define whether or not the cytolytic activity of LAK cells as measured in vitro correlated directly with the in vivo anti-tumor efficacy of adoptively transferred LAK cells. LAK cells plus RIL 2 could mediate marked reductions of established pulmonary metastases in mice rendered T cell deficient by adult thymectomy and lethal, total body irradiation followed by reconstitution with T cell-depleted bone marrow and spleen cells. Thus there was no requirement for additional T lymphocytes of host origin for successful therapy with adoptively transferred LAK cells plus RIL 2. Fresh splenocytes depleted of T cells by anti-Thy-1.2 monoclonal antibody plus complement generated LAK cells that were as highly lytic to fresh tumor in vitro and were as effective in reducing established pulmonary metastases as those generated from untreated or complement-treated splenocytes. Thus, the precursor to LAK cells with anti-tumor activity in vitro and in vivo did not express the Thy-1 antigenic marker. In contrast, treatment of LAK effector cells (those generated from a 3-day incubation of fresh, normal splenocytes in RIL 2) with anti-Thy-1.2 antibody plus complement reduced or abolished their in vitro cytolytic activity.

• Research Organization: National Cancer Institute, Bethesda, MD
• OSTI ID: 5650996
• Journal Information: J. Immunol.; (United States), Vol. 10
• Country of Publication: United States
• Language: English

Related Subjects

63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
LYMPHOCYTES
IMMUNOTHERAPY
TUMOR CELLS
LYSIS
ANTIGENS
BONE MARROW CELLS
CELL DIFFERENTIATION
COMPLEMENT
IN VIVO
LETHAL IRRADIATION
LYMPHOKINES
METASTASES
MICE
MONOCLONAL ANTIBODIES
SPLEEN CELLS
THYMECTOMY
WHOLE-BODY IRRADIATION
ANIMAL CELLS
ANIMALS
ANTIBODIES
BIOLOGICAL MATERIALS
BLOOD
BLOOD CELLS
BODY FLUIDS
CONNECTIVE TISSUE CELLS
EXTERNAL IRRADIATION
GROWTH FACTORS
IRRADIATION
LEUKOCYTES
MAMMALS
MATERIALS
MEDICINE
MITOGENS
ORGANIC COMPOUNDS
PROTEINS
RODENTS
SOMATIC CELLS
SURGERY
THERAPY
VERTEBRATES
560152* - Radiation Effects on Animals- Animals